Levetiracetam Treatment of Tardive Dyskinesia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00291213

Enrollment

Registered

2006-02-13

Start date

Unknown

Completion date

Unknown

Last updated

2014-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tardive Dyskinesia

Brief summary

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Interventions

DRUGlevetiracetam

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

meet Glazer Morgenstern criteria for TD -

Exclusion criteria

none \-

Design outcomes

Primary

Measure	Time frame
Abnormal Involuntary Movement Scale (AIMS) Total Score	12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026